Your browser doesn't support javascript.
loading
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose-escalation study.
Yan, Diqin; Niu, Suping; Hu, Dingyuan; Dong, Wenliang; Sun, Yunjuan; Wang, Qian; Wang, Simin; Gu, Qun; Liu, Gang; Wang, Jiaxue; Chen, Liming; Lv, Jie; Zheng, Qingshan; Song, Haifeng; Fang, Yi.
Affiliation
  • Yan D; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Niu S; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  • Hu D; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Dong W; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Sun Y; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  • Wang Q; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Wang S; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  • Gu Q; Beijing United-Power Pharma Tech Co., Ltd, Beijing, China.
  • Liu G; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Wang J; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Chen L; Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
  • Lv J; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
  • Zheng Q; Department of Pharmacy, Peking University People's Hospital, Beijing, China.
  • Song H; Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, China.
  • Fang Y; Clinical Trial Institution, Peking University People's Hospital, Beijing, China.
Expert Opin Investig Drugs ; 32(2): 161-170, 2023 Feb.
Article de En | MEDLINE | ID: mdl-36755413
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Anticorps monoclonaux humanisés Type d'étude: Clinical_trials / Prognostic_studies Limites: Adult / Humans Langue: En Journal: Expert Opin Investig Drugs Sujet du journal: TERAPIA POR MEDICAMENTOS Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Anticorps monoclonaux humanisés Type d'étude: Clinical_trials / Prognostic_studies Limites: Adult / Humans Langue: En Journal: Expert Opin Investig Drugs Sujet du journal: TERAPIA POR MEDICAMENTOS Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni